Safe Fertility vs Ramkhamhaeng Hospital: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Safe Fertility Group Public Company Limited (SAFE.BK)

Q3 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

August 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Latest20 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Ramkhamhaeng Hospital Public Company Limited (RAM.BK)

Q3 202620 Jul – 23 Sep 2026

▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.
This is a major acquisition that directly boosts RAM's financials and growth story.
RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.
This is the actual earnings result that shows the impact of RAM's consolidation strategy.
Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.
This is a key competitive threat that pressures RAM's pricing and profitability.
Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.
This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

August 202620 Jul – 23 Sep 2026

▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.
This is a major acquisition that directly boosts RAM's financials and growth story.
RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.
This is the actual earnings result that shows the impact of RAM's consolidation strategy.
Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.
This is a key competitive threat that pressures RAM's pricing and profitability.
Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.
This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

Latest20 Jul – 23 Sep 2026

▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.
This is a major acquisition that directly boosts RAM's financials and growth story.
RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.
This is the actual earnings result that shows the impact of RAM's consolidation strategy.
Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.
This is a key competitive threat that pressures RAM's pricing and profitability.
Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.
This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.